Diabetic Medicine · 2014 · 40 citations · 20 references
PharmacyInternal MedicinePharmacoeconomicsCost-effectiveness AnalysisHealth Technology AssessmentPharmacoeconomic ModelingBlood Glucose MonitoringContinuous Glucose MonitoringDiabetes MellitusEconomic EvaluationGlycemic MonitoringPharmacoeconomic EvaluationContinuous Glucose Monitoring Guided TherapyContinuous Subcutaneous InfusionContinuous Subcutaneous Insulin InfusionCost-effectivenessCost-effectiveness Of Glucose MonitoringDirect Treatment CostsGlucose MonitoringLife-years Gained Modeling
AIM: To evaluate the clinical benefits and cost-effectiveness of the sensor-augmented pump compared with self-monitoring of plasma glucose plus continuous subcutaneous insulin infusion in people with Type 1 diabetes. METHODS: The CORE Diabetes Model was used to simulate disease progression in a cohort of people with baseline characteristics taken from a published meta-analysis. Direct and indirect costs for 2010-2011 were calculated from a societal payer perspective, with cost-effectiveness calculated over the patient's lifetime. Discount rates of 3% per annum were applied to the costs and the clinical outcomes. RESULTS: Use of the sensor-augmented pump was associated with an increase in mean discounted, quality-adjusted life expectancy of 0.76 quality-adjusted life years compared with continuous subcutaneous insulin infusion (13.05 ± 0.12 quality-adjusted life years vs 12.29 ± 0.12 quality-adjusted life years, respectively). Undiscounted life expectancy increased by 1.03 years for the sensor-augmented pump compared with continuous subcutaneous insulin infusion. In addition, the onset of complications was delayed (by a mean of 1.15 years) with use of the sensor-augmented pump. This analysis resulted in an incremental cost-effectiveness ratio of 367,571 SEK per quality-adjusted life year gained with the sensor-augmented pump. The additional treatment costs related to the use of the sensor-augmented pump were partially offset by the savings attributable to the reduction in diabetes-related complications and the lower frequency of self-monitoring of plasma glucose. CONCLUSIONS: Analysis using the CORE Diabetes Model showed that improvements in glycaemic control associated with sensor-augmented pump use led to a reduced incidence of diabetes-related complications and a longer life expectancy. Use of the sensor-augmented pump was associated with an incremental cost-effectiveness ratio of 367,571 SEK per quality-adjusted life year gained, which is likely to represent good value for money in the treatment of Type 1 diabetes in Sweden.
20
Global healthcare expenditure on diabetes for 2010 and 2030
Ping Zhang, Xinzhi Zhang, Jonathan B. Brown et al. · Diabetes Research and Clinical Practice · 2010 · 1.1K citations
Trang T. Ly, Jennifer A. Nicholas, Adam Retterath et al. · JAMA · 2013 · 412 citations · Full text
Executive Summary: Standards of Medical Care in Diabetes—2014
Diabetes Care · 2013 · 300 citations · Full text